https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1-AKT axis-mediated glycolysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42661 Wed 31 Aug 2022 13:44:21 AEST ]]> Ancient DNA from marine sediments: precautions and considerations for seafloor coring, sample handling and data generation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36776 Wed 29 Mar 2023 12:02:43 AEDT ]]> Evaluation of epigenetic methylation biomarkers for the detection of colorectal cancer using droplet digital PCR https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52394 Wed 28 Feb 2024 15:33:56 AEDT ]]> The Future of Biomarkers in Veterinary Medicine: Emerging Approaches and Associated Challenges https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52876 Wed 28 Feb 2024 11:01:07 AEDT ]]> Serum prednisolone levels as a marker of oral corticosteroid adherence in severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45112 Wed 26 Oct 2022 13:25:03 AEDT ]]> Examining for cavum septum pellucidum and ventricular enlargement in retired elite-level rugby league players https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51178 Wed 24 Apr 2024 12:15:17 AEST ]]> Cancer proteomics and the elusive diagnostic biomarkers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46956 Wed 19 Jul 2023 14:21:24 AEST ]]> Behavioral, blood, and magnetic resonance imaging biomarkers of experimental mild traumatic brain injury https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30321 Wed 16 May 2018 13:39:09 AEST ]]> Analysis of Fat1 cadherin and identification of novel biomarkers for acute leukemia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14447 Wed 15 May 2019 09:58:18 AEST ]]> Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37079 Wed 15 Dec 2021 16:07:28 AEDT ]]> Molluscan biomonitor for quantification and impact assessment of estrogenic and metallic contaminants in Australian marine ecosystems https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9323 Wed 11 Apr 2018 15:21:23 AEST ]]> Identification of a 5-protein biomarker molecular signature for predicting Alzheimer's disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4456 Wed 11 Apr 2018 14:49:36 AEST ]]> Fasting whole blood fatty acid profile and risk of type 2 diabetes in adults: a nested case control study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16813 Wed 11 Apr 2018 14:42:05 AEST ]]> Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease meuroimaging initiative (ADNI) plasma proteome dataset https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15120 Wed 11 Apr 2018 14:37:46 AEST ]]> Unveiling clusters of RNA transcript pairs associated with markers of Alzheimer's disease progression https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15137 Wed 11 Apr 2018 14:14:06 AEST ]]> In Vivo brain magnetic resonance spectroscopy: a measurement of biomarker sensitivity to post-processing algorithms https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21275 in vivo brain magnetic resonance spectroscopy biomarkers is investigated with respect to parameter values for two key stages of post-acquisitional processing. Our effort is specifically motivated by the lack of consensus on approaches and parameter values for the two critical operations, water resonance removal, and baseline correction. The different stages of data processing also introduce varying levels of uncertainty and arbitrary selection of parameter values can significantly underutilize the intrinsic differences between two classes of signals. The sensitivity of biomarkers points to the need for a better understanding of how all stages of post-acquisitional processing affect biomarker discovery and ultimately, clinical translation. Our results also highlight the possibility of optimizing biomarker discovery by the careful selection of parameters that best reveal class differences. Using previously reported data and biomarkers, our results demonstrate that small changes in parameter values affect the statistical significance and corresponding effect size of biomarkers. Consequently, it is possible to increase the strength of biomarkers by selecting optimal parameter values in different spectral intervals. Our analyses with a previously reported data set demonstrate an increase in effect sizes for wavelet-based biomarkers of up to 36%, with increases in classification performance of up to 12%.]]> Wed 11 Apr 2018 12:19:42 AEST ]]> Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29771 P<0.0001). Delayed response post first scan was seen in 2 out of 37 (5%) deemed progressive (PD) by RECIST and 2 out of 14 (14%) deemed PD by irRC. Modified CHOI criteria showed response of 38% (14 out of 37). Change in tumour size and density on first follow-up assessment was associated with OS with each 1000 mm² increase in tumour size from baseline increasing the hazard of dying by 25.9% (HR=1.259, (95% CI=1.116-1.420), P=0.0002). Similarly, each 20HU increase in density increased the HR by 15% (HR=1.15, (95% CI 1.045-1.260), P=0.004). Response defined by any criteria had superior OS (CHOI P=0.0084; mCHOI P=0.0183; irRC P<0.0001 and RECIST P=0.0003). Conclusions: Response by any criterion was prognostic. Novel patterns of response and changes on treatment in tumour density suggest complex anti-tumour responses to immunotherapy.]]> Wed 11 Apr 2018 12:06:49 AEST ]]> Biochemical validation of the older Australian's food frequency questionnaire using carotenoids and vitamin E https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16953 Wed 11 Apr 2018 11:42:24 AEST ]]> A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16805 Wed 11 Apr 2018 11:29:15 AEST ]]> Biomarkers in melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:6914 Wed 11 Apr 2018 11:22:08 AEST ]]> Reference intervals for non-fasting CVD lipids and inflammation markers in pregnant Indigenous Australian women https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30654 Wed 11 Apr 2018 09:39:59 AEST ]]> Can biomarkers help us hit targets in difficult-to-treat asthma? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34558 Wed 10 Nov 2021 15:14:18 AEDT ]]> Serum protein profiles of patients with lung cancer of different histological types https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28661 Wed 09 Mar 2022 16:03:03 AEDT ]]> Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33054 5 % BMD loss after 1 year had triple the percentage increase in MRS FF at 6 months (61.1 % vs. 20.9 %, p = 0.19). Conclusions: Changes are observed on L-spine MRI after 6 months of ADT. Further investigation is warranted of MRS change as a potential predictive biomarker for later BMD loss.]]> Wed 09 Mar 2022 16:02:16 AEDT ]]> Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34942 Wed 09 Feb 2022 15:56:55 AEDT ]]> Deep time-resolved proteomic and phosphoproteomic profiling of cigarette smoke-induced chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35918 Wed 07 Jul 2021 12:41:58 AEST ]]> Assessment of risk factors and identification of potential biomarkers associated with breast cancer-related lymphedema in Malaysian breast cancer survivors https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50015 Wed 06 Mar 2024 14:17:28 AEDT ]]> Neurofilament light chain (Nfl) in blood—a biomarker predicting unfavourable outcome in the acute phase and improvement in the late phase after stroke https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50139 Wed 05 Jul 2023 12:54:49 AEST ]]> In the search for integrative biomarker of resilience to psychological stress https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27088 Wed 04 Sep 2019 09:39:52 AEST ]]> C1q and mobility score in predicting sarcopenia in an Australian cohort of cancer surgery patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52162 Wed 04 Oct 2023 10:50:47 AEDT ]]> Plasma neurofilament light chain levels predict improvement in late phase after stroke https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49081 Wed 03 May 2023 16:22:13 AEST ]]> A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis–Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50684 Wed 01 May 2024 15:04:24 AEST ]]> Identification of biomarkers and genetic approaches toward chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47835 Wed 01 Feb 2023 14:10:48 AEDT ]]> Dietary Assessment and Metabolomic Methodologies in Human Feeding Studies: A Scoping Review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54375 Tue 20 Feb 2024 20:24:25 AEDT ]]> Extracellular vesicles- crucial players in human pregnancy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54348 Tue 20 Feb 2024 16:20:31 AEDT ]]> Individual patient profiling using clinical and neuroradiological biomarkers in acute ischemic stroke: application of advanced multimodal neuroimaging https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29075 Tue 17 Sep 2019 15:21:28 AEST ]]> Oxidative stress in liver diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41999 Tue 16 Aug 2022 16:44:33 AEST ]]> Back to the Eosinophil: Resolvin Spatiotemporal Regulation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54156 Tue 06 Feb 2024 12:11:30 AEDT ]]> Successful cognitive aging is associated with thicker anterior cingulate cortex and lower tau deposition compared to typical aging https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54142 Tue 06 Feb 2024 11:57:57 AEDT ]]> Time-resolved proteomic profiling of cigarette smoke-induced experimental chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43823 Tue 04 Oct 2022 11:04:24 AEDT ]]> Airway microbiome and serum metabolomics analysis identify differential candidate biomarkers in allergic rhinitis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45550 Tue 01 Nov 2022 10:56:22 AEDT ]]> A novel feature selection approach for data integration analysis: applications to transcriptomics study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24585 Thu 29 Nov 2018 10:14:05 AEDT ]]> Airway surfactant protein D deficiency in adults with severe asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26089 Thu 28 Oct 2021 13:03:49 AEDT ]]> Contemporary Concise Review 2019: Asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41149 Thu 28 Jul 2022 09:13:20 AEST ]]> Microbiome and Metabolic Features of Tissues and Feces Reveal Diagnostic Biomarkers For Colorectal Cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50515 Thu 27 Jul 2023 14:34:40 AEST ]]> A systematic review of the validity of dietary assessment methods in children when compared with the method of doubly labelled water https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37208 n = 306 children) met the selection criteria. Five studies were carried out in children aged 5–11 years with dietary intake of children reported by parents/caregivers. The most common dietary assessment methods used were food frequency questionnaires (n = 5) and weighed food records (n = 4). All methods were found to have some level of misreporting. Child characteristics including weight status, age, and sex were not found to consistently influence the accuracy of reported EI. Five studies employing technology-assisted approaches for assessing dietary intake in children were identified and reported mixed findings. Validity studies using DLW remain sparse in the literature. Studies including participants less than 5 years or older than 11 years, and from diverse ethnicities and socioeconomic backgrounds are warranted to explore other demographic differences that may affect the accuracy of dietary assessment methods. While reported in few studies, technology-assisted methods were found to perform equally well in estimating intakes when compared to DLW and other traditional forms of dietary assessment.]]> Thu 26 May 2022 16:07:38 AEST ]]> Circulating markers to assess nutritional therapy in cystic fibrosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:660 Thu 25 Jul 2013 09:10:27 AEST ]]> Non-coding RNAs in endometriosis: a narrative review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37556 Thu 18 Feb 2021 10:04:21 AEDT ]]> A review of natural therapies potentially relevant in triple negative breast cancer aimed at targeting cancer cell vulnerabilities https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38357 Thu 09 Sep 2021 12:21:31 AEST ]]> Assessing tobacco use in an African population: serum and urine cotinine cut-offs from South Africa https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46909 Thu 08 Dec 2022 08:26:11 AEDT ]]> T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52202 Thu 05 Oct 2023 10:09:05 AEDT ]]> The changing role of pathology in breast cancer diagnosis and treatment https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15320 Sat 24 Mar 2018 08:26:36 AEDT ]]> Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12974 Sat 24 Mar 2018 08:16:09 AEDT ]]> Neurotrophins and their receptors in breast cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21423 NTR death receptor. Preclinical studies have shown that targeting neurotrophins and their receptors induce an inhibition of breast cancer cell survival, proliferation and invasion. Furthermore, targeting neurotrophins may also decrease tumor-induced cancer pain and this additional effect further strengthens their clinical relevance.]]> Sat 24 Mar 2018 08:05:02 AEDT ]]> The role of biomarkers in the management of airways disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18875 Sat 24 Mar 2018 08:03:15 AEDT ]]> The role of olfactory challenge tests in incipient dementia and clinical trial design https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18865 Sat 24 Mar 2018 08:03:15 AEDT ]]> Profilin-1 overexpression in MDA-MB-231 breast cancer cells is associated with alterations in proteomics biomarkers of cell proliferation, survival, and motility as revealed by global proteomics analyses https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19788 cell proliferation (FKPB1A, HDGF, MIF, PRDX1, TXNRD1, LGALS1, STMN1, LASP1, S100A11, S100A6), survival (HSPE1, HSPB1, HSPD1, HSPA5 and PPIA, YWHAZ, CFL1, NME1) and motility (CFL1, CORO1B, PFN2, PLS3, FLNA, FLNB, NME2, ARHGDIB). In view of the pleotropic effects of PFN1 overexpression in breast cancer cells as suggested by these new findings, we propose that PFN1-induced phenotypic changes in cancer cells involve multiple mechanisms. Our data reported here might also offer innovative strategies for identification and validation of novel therapeutic targets and companion diagnostics for persons with, or susceptibility to, breast cancer.]]> Sat 24 Mar 2018 07:57:13 AEDT ]]> Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20620 Sat 24 Mar 2018 07:55:44 AEDT ]]> Circulating tumor cell detection in high-risk non-metastatic prostate cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21027 Sat 24 Mar 2018 07:50:34 AEDT ]]> Molecular organic matter in speleothems and its potential as an environmental proxy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5532 100 ka), can be recovered at temporal resolutions of < 10 yr, and show meaningful changes through time. This approach is therefore of considerable potential value to Quaternary science.]]> Sat 24 Mar 2018 07:46:41 AEDT ]]> Efficacy of the omega-3 index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26621 Sat 24 Mar 2018 07:34:00 AEDT ]]> What are they really eating? A review on new approaches to dietary intake assessment and validation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29530 Sat 24 Mar 2018 07:32:29 AEDT ]]> NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27223 M-H = 0.08). These results point to a role of the NLRP3 inflammasome and its related cytokine IL1B in the response to interferon beta in patients with relapsing-remitting multiple sclerosis.]]> Sat 24 Mar 2018 07:32:24 AEDT ]]> Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28945 Sat 24 Mar 2018 07:31:25 AEDT ]]> In the search for integrative biomarker of resilience to psychological stress https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30855 Sat 24 Mar 2018 07:26:36 AEDT ]]> Age and socioeconomic gradients of health of Indian adults: an assessment of self-reported and biological measures of health https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24621 Sat 24 Mar 2018 07:11:54 AEDT ]]> Flucloxacillin worsens while imipenem–cilastatin protects against vancomycin-induced kidney injury in a translational rat model https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54577 Sat 02 Mar 2024 10:02:38 AEDT ]]> Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52824 Mon 30 Oct 2023 09:18:14 AEDT ]]> High preoperative levels of circulating SFRP5 predict better prognosis in colorectal cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49722 Mon 29 May 2023 15:20:47 AEST ]]> Environmental impacts of habitat fragmentation and heavy metal contamination on estuarine seagrass communities https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22437 Mon 26 Apr 2021 10:24:41 AEST ]]> Anemia and socioeconomic status among older adults in the Study on global AGEing and adult health (SAGE) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51984 Mon 25 Sep 2023 14:57:03 AEST ]]> Genetic algorithm-based ensemble methods for large-scale biological data classification https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27427 Mon 23 Sep 2019 13:35:41 AEST ]]> Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48602 Mon 01 May 2023 15:45:16 AEST ]]> Urinary biomarkers of dietary intake: a review https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41231 Fri 29 Jul 2022 13:41:22 AEST ]]> Moving towards a Treatable Traits model of care for the management of obstructive airways diseases https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48632 Fri 24 Mar 2023 10:57:01 AEDT ]]> A systematic review of technology-based dietary intake assessment validation studies that include carotenoid biomarkers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29922 Fri 24 Aug 2018 09:03:14 AEST ]]> A sputum gene expression signature predicts oral corticosteroid response in asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34249 Fri 22 Feb 2019 16:55:30 AEDT ]]> Genetic estimates of correlation and causality between blood-based biomarkers and psychiatric disorders https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51745 Fri 15 Sep 2023 18:22:09 AEST ]]> Inability of current dosing to achieve carboplatin therapeutic targets in people with advanced non-small cell lung cancer: impact of systemic inflammation on carboplatin exposure and clinical outcomes https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40009 n = 61) were analysed using non-linear mixed modelling. Covariate analysis was performed to investigate the impact of standard and novel patient characteristics of carboplatin pharmacokinetics. A Monte Carlo simulation of 100,000 representative NSCLC patients evaluated the ability of the Calvert formula and novel dosing strategies to achieve the targeted therapeutic range. The associations between systemic inflammation and chemotherapy drug utilisation (cycles received, relative dose intensity (RDI) and second-line uptake) and clinical endpoints were also investigated in the pharmacokinetic cohort, and two independent cohorts of people with advanced NSCLC from the Chemotherapy Dosing in Cancer-Related Inflammation (CDCRI) database that were administered carboplatin–paclitaxel (n = 37) or carboplatin–gemcitabine (n = 358). Results: In all cohorts, 25–53% of people had elevated systemic inflammation (NLR > 5 or PLR > 300). In the pharmacokinetic cohort, no patients achieved the desired therapeutic target of carboplatin. Carboplatin exposure was related to renal function, as estimated using the Cockcroft–Gault formula, albumin and inflammation (NLR). In the pharmacokinetic cohort, increasing carboplatin area under the curve (AUC) correlated with greater reductions in red blood cells and haemoglobin. In this cohort, the average measured AUC of partial responders was 2.4 mg·min/mL. Also in the pharmacokinetic cohort, only 12% of people with an NLR > 5 received four or more cycles of chemotherapy, compared with 62% of patients with an NLR ≤ 5 (p < 0.001). For people in the CDCRI cohort receiving carboplatin–gemcitabine, those with an NLR > 5 also received less cycles (four or more cycles, 41% vs. 60%; p < 0.01) as well as less second-line chemotherapy (46% vs. 60%; p = 0.02) compared with patients without inflammation. People in the pharmacokinetic cohort with an NLR > 5 had 12 months less median survival compared with people with an NLR ≤ 5 (6.5 vs. 18 months; p = 0.08). Similarly, overall survival was significantly shortened in people in the CDCRI cohort receiving carboplatin–gemcitabine with an NLR > 5 compared with those with an NLR ≤ 5 (7 vs. 12 months; p < 0.001), and Cox regression analysis showed a 1.5-fold (1.3–2.1; p < 0.001) increased hazard of death associated with the increased systemic inflammation. Simulations of the newly developed model-based and Calvert dosing assessed the ability to reach this study’s proposed actual target AUC of 2.2–2.6 mg·min/mL. These showed current Calvert dosing was predicted to result in substantial overexposure in patients with high systemic inflammation. The newly developed model showed equivalent levels of carboplatin therapeutic target achievement across the spectrum of inflammation observed in the lung cancer population. Conclusion: An alternate model-based dosing strategy for carboplatin was developed and is predicted to result in consistent drug exposure across the population and improve attainment of therapeutic targets. Further studies of this new model are warranted in people with advanced NSCLC.]]> Fri 15 Jul 2022 11:35:17 AEST ]]> Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48913 Fri 14 Apr 2023 18:21:40 AEST ]]> Sputum Metabolomic Profiling Reveals Metabolic Pathways and Signatures Associated With Inflammatory Phenotypes in Patients With Asthma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47306 Fri 13 Jan 2023 10:52:32 AEDT ]]> Precision oncology in surgery: patient selection for operable pancreatic cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46225 Fri 09 Dec 2022 14:48:55 AEDT ]]> ELISA-based quantification of neurotrophic growth factors in urine from prostate cancer patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40341 Fri 08 Jul 2022 10:33:39 AEST ]]> Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53590 PD >NG, p=0.0046). Post-hoc analysis indicated significantly higher plasma NfL levels in the T2D [12.4 (5.21) pg/mL] group than in the PD [10.2 (4.13) pg/mL] and NG [8.37 (5.65) pg/mL] groups. The relationship between diabetes status and NfL remained significant after adjusting for age, sex, BMI, HOMA-IR and physical activity (adjusted r2 = 0.271, p = 0.035). Conclusions: These results show biomarker evidence of neurodegeneration in adults at risk or with T2D. Larger sample size and longitudinal analysis are required to better understand the application of NfL in people with risk and overt T2D.]]> Fri 08 Dec 2023 15:47:18 AEDT ]]> Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44103 Fri 07 Oct 2022 13:51:30 AEDT ]]> Heparin Administration, but Not Myocardial Ischemia or Necrosis, Leads to Midkine Elevation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41547 Fri 05 Aug 2022 14:23:18 AEST ]]> Early identification of acute kidney injury in Russell's viper (Daboia russelii) envenoming using renal biomarkers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45713 Fri 04 Nov 2022 10:27:59 AEDT ]]> Low blood-as levels and selected genotypes appears to be promising biomarkers for occurrence of colorectal cancer in women https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49791 Fri 02 Jun 2023 17:14:07 AEST ]]>